Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

Documenti analoghi

• Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia
  di: Jabbour, Elias J, et al.
  Pubblicazione: (2013)
• Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications
  di: Jabbour, Elias, et al.
  Pubblicazione: (2008)
• The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
  di: Nazha, Aziz, et al.
  Pubblicazione: (2013)
• Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A Review of Tyrosine Kinase Inhibitors
  di: Jabbour, Elias, et al.
  Pubblicazione: (2010)
• Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
  di: Jabbour, Elias, et al.
  Pubblicazione: (2015)